SLDB

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 14.29 USD with a low forecast of 9.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Solid Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Solid Biosciences Inc. EPS for the last quarter amounts to -0.48 USD, decreased -39.24 % YoY.

Solid Biosciences Inc (SLDB) has 100 emplpoyees as of January 10 2026.

Today SLDB has the market capitalization of 412.15M USD.